Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluMos-v2 in Healthy Adults
NCT05968989Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2023
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of FluMos-v2 in influenza (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety and Tolerability at 40 weeks. Started Aug 2023; status: completed.
02
Drugs
FluMos-v2
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05968989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05968989.